Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Vaxart, Inc.NASDAQ: VXRT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.48M fell 39.7% year over year, behind the -25.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.

Context

  • Stock-based compensation amounted to 3.5% of revenue in FY2025, down 36.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -39.7% toward the trailing-twelve-month pace of -25.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.48M-13.6% QoQ
Last fiscal yearDec 2025
$8.31M-27.7% YoY
LTMMar 2026
$7.34M-25.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.7%——
1 year-27.7%——
3-year CAGR-15.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.31M USD
Year-over-year change
-27.7%
4-year CAGR
-1.6%

Stock-Based Compensation vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's LTM Mar 2026 stock-based compensation of $7.34M is the 6th largest of the 10 companies compared; the peer median is $10.76M.
  • Its year-over-year change of -25.5% is the 7th highest of 10, against a peer median of -12.1%.
  • Stock-based compensation amounts to 2.9% of revenue for VXRT, versus a peer median of 117.5%.
VXRT Competitors Peer median
Stock-Based Compensation for VXRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$22.45M -34.1%+7.7%33.9%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$13.93M -47.2%-30.3%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M -11.0%+88.9%—
IMUXImmunic, Inc.LTM Mar 2026$11.29M +44.4%+3.8%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$10.76M -2.0%+37.0%117.7%
VXRTVaxart, Inc.LTM Mar 2026$7.34M -25.5%-15.1%2.9%
CBUSCibus, Inc.LTM Mar 2026$7.26M -32.3%+27.0%169.4%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$5.81M -25.3%-16.6%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$4.61M +14.2%—117.2%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$2.1M -12.1%+36.1%—
Peer median (excluding VXRT) $10.76M-12.1%+17.4%117.5%

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.47M)(107.76M)(82.47M)(66.95M)16.33M
Depreciation & Amortization4.21M5.81M8.62M8.85M8.58M
Deferred Income Tax3.09M4.09M000
Stock-Based Compensation8.87M13.59M14.13M11.5M8.31M
Change in Working Capital(2.12M)(4.7M)(10.85M)3.26M(22.56M)
Accounts Receivables263K51K(2.99M)(2.75M)(39.38M)
Inventory0(7.11M)000
Accounts Payables1.63M357K(2.44M)5.27M14.64M
Other Working Capital(4.01M)2M(5.42M)742K2.17M
Other Non-Cash Items(3.41M)(5.81M)106K(1.43M)(2.94M)
Operating Cash Flow(59.83M)(94.78M)(70.45M)(44.76M)7.71M
Capital Expenditures(5.16M)(9.6M)(1.87M)(554K)(145K)
Acquisitions (Net)(4.83M)10.81M120K00
Purchases of Investments(44.81M)(55.01M)(27.5M)(54.33M)(19.03M)
Sales of Investments5.7M44.2M73.2M43.5M40M
Other Investing Activities0(10.81M)0(9.95M)(4.2M)
Investing Cash Flow(49.1M)(20.42M)43.95M(21.32M)16.63M
Debt Repayment00000
Common Stock Issued122.21M17.24M15.03M56.78M4.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M225K213K(214K)(199K)
Financing Cash Flow125.8M17.46M15.24M56.56M4.24M
Effect of Forex Changes00000
Net Change in Cash16.88M(97.73M)(11.26M)(9.53M)28.59M
Free Cash Flow(64.99M)(104.38M)(72.32M)(45.32M)7.57M

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.